Anya K Bershad1, Scott T Schepers2, Michael P Bremmer2, Royce Lee2, Harriet de Wit3. 1. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois; Interdisciplinary Scientist Training Program, University of Chicago, Chicago, Illinois. 2. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois. 3. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois. Electronic address: hdew@uchicago.edu.
Abstract
BACKGROUND: Numerous anecdotal reports suggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing, improves mood and cognitive function. These effects are consistent both with the known actions of LSD on serotonin receptors and with limited evidence that higher doses of LSD (100-200 μg) positively bias emotion processing. Yet, the effects of such subthreshold doses of LSD have not been tested in a controlled laboratory setting. As a first step, we examined the effects of single very low doses of LSD (0-26 μg) on mood and behavior in healthy volunteers under double-blind conditions. METHODS:Healthy young adults (N = 20) attended 4laboratory sessions during which they received 0 (placebo), 6.5, 13, or 26 μg of LSD in randomized order at 1-week intervals. During expected peak drug effect, they completed mood questionnaires and behavioral tasks assessing emotion processing and cognition. Cardiovascular measures and body temperature were also assessed. RESULTS:LSD produced dose-related subjective effects across the 3 doses (6.5, 13, and 26 μg). At the highest dose, the drug also increased ratings of vigor and slightly decreased positivity ratings of images with positive emotional content. Other mood measures, cognition, and physiological measures were unaffected. CONCLUSIONS: Single microdoses of LSD produced orderly dose-related subjective effects in healthy volunteers. These findings indicate that a threshold dose of 13 μg of LSD might be used safely in an investigation of repeated administrations. It remains to be determined whether the drug improves mood or cognition in individuals with symptoms of depression.
RCT Entities:
BACKGROUND: Numerous anecdotal reports suggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing, improves mood and cognitive function. These effects are consistent both with the known actions of LSD on serotonin receptors and with limited evidence that higher doses of LSD (100-200 μg) positively bias emotion processing. Yet, the effects of such subthreshold doses of LSD have not been tested in a controlled laboratory setting. As a first step, we examined the effects of single very low doses of LSD (0-26 μg) on mood and behavior in healthy volunteers under double-blind conditions. METHODS: Healthy young adults (N = 20) attended 4 laboratory sessions during which they received 0 (placebo), 6.5, 13, or 26 μg of LSD in randomized order at 1-week intervals. During expected peak drug effect, they completed mood questionnaires and behavioral tasks assessing emotion processing and cognition. Cardiovascular measures and body temperature were also assessed. RESULTS: LSD produced dose-related subjective effects across the 3 doses (6.5, 13, and 26 μg). At the highest dose, the drug also increased ratings of vigor and slightly decreased positivity ratings of images with positive emotional content. Other mood measures, cognition, and physiological measures were unaffected. CONCLUSIONS: Single microdoses of LSD produced orderly dose-related subjective effects in healthy volunteers. These findings indicate that a threshold dose of 13 μg of LSD might be used safely in an investigation of repeated administrations. It remains to be determined whether the drug improves mood or cognition in individuals with symptoms of depression.
Authors: Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak Journal: Ther Adv Psychopharmacol Date: 2016-03-18
Authors: Katrin H Preller; Marcus Herdener; Thomas Pokorny; Amanda Planzer; Rainer Kraehenmann; Philipp Stämpfli; Matthias E Liechti; Erich Seifritz; Franz X Vollenweider Journal: Curr Biol Date: 2017-01-26 Impact factor: 10.834
Authors: Anthony G Romano; Jennifer L Quinn; Luchuan Li; Kuldip D Dave; Emmanuelle A Schindler; Vincent J Aloyo; John A Harvey Journal: Psychopharmacology (Berl) Date: 2010-09-09 Impact factor: 4.530
Authors: Patrick C Dolder; Yasmin Schmid; Manuel Haschke; Katharina M Rentsch; Matthias E Liechti Journal: Int J Neuropsychopharmacol Date: 2015-06-24 Impact factor: 5.176
Authors: Peter Gasser; Dominique Holstein; Yvonne Michel; Rick Doblin; Berra Yazar-Klosinski; Torsten Passie; Rudolf Brenneisen Journal: J Nerv Ment Dis Date: 2014-07 Impact factor: 2.254
Authors: Calvin Ly; Alexandra C Greb; Lindsay P Cameron; Jonathan M Wong; Eden V Barragan; Paige C Wilson; Kyle F Burbach; Sina Soltanzadeh Zarandi; Alexander Sood; Michael R Paddy; Whitney C Duim; Megan Y Dennis; A Kimberley McAllister; Kassandra M Ori-McKenney; John A Gray; David E Olson Journal: Cell Rep Date: 2018-06-12 Impact factor: 9.423
Authors: Anya K Bershad; Katrin H Preller; Royce Lee; Sarah Keedy; Jamie Wren-Jarvis; Michael P Bremmer; Harriet de Wit Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2019-12-20
Authors: Simon B Goldberg; Benjamin Shechet; Christopher R Nicholas; Chi Wing Ng; Geetanjali Deole; Zhuofan Chen; Charles L Raison Journal: Psychol Med Date: 2020-11-04 Impact factor: 7.723
Authors: Justin M Saunders; Alaina M Jaster; Hiba Z Vohra; Mario de la Fuente Revenga; Jennifer Jimenez; Alberto Fernández-Teruel; Jennifer T Wolstenholme; Patrick M Beardsley; Javier González-Maeso Journal: Psychopharmacology (Berl) Date: 2021-08-04 Impact factor: 4.530